Development of nonalcoholic hepatopathy: Contributions of oxidative stress and advanced glycation end products

International Journal of Molecular Sciences

Volumn 14, Issue 10, 2013, Pages 19846-19866

  Santos, Juliana Célia de F ^a   Valentim, Iara B ^a,b   de Araújo, Orlando R P ^a   Ataide, Terezinha da R ^a   Goulart, Marília O F ^a  

^a FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^b Federal Institute for Education   (Brazil)

Author keywords

AGEs; Liver; Molecular mechanism of biological activity; Nonalcoholic fatty liver disease; Oxidative stress

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYTOCHROME P450 2E1; HORMONE SENSITIVE LIPASE; INSULIN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL ACTIVATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY LIVER; GLYCATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; IMMUNOREGULATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; STEATOSIS; STELLATE CELL;

ANIMALS; FATTY LIVER; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 84885093994     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141019846     Document Type: Review

References (62)

1. Basta, G.; Navarra, T.; Simone, P.; Turco, S.; Gastaldelli, A.; Filipponi, F. What is the role of the receptor for advanced glycation end products-ligand axis in liver injury? Liver Transpl. 2011, 17, 633-640.
2. Jaeschke, H.; Ramachandran, A. Reactive oxygen species in the normal and acutely injured liver. J. Hepatol. 2011, 55, 227-228.
3. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114, 147-152.
4. Anstee, Q.M.; Goldin, R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006, 87, 1-16.
5. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american gastroenterological association, american association for the study of liver diseases, and american college of gastroenterology. Hepatology 2012, 55, 2005-2023.
6. International Diabetes Federation. Available online: http://www.diabetesatlas.org (accessed on 1 June 2012).
7. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Available online: http://www.scielo.br/scielo.php?script=sci_pdf&pid=S0066-782X2005000700001&lng=en&nrm= iso&tlng=pt (accessed on 22 September 2013).
8. Souza, M.R.A.; Diniz, M.F.F.M.; Medeiros-Filho, J.E.M.; Araújo, M.S.T. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq. Gastroenterol. 2012, 49, 89-96.
9. Negre-Salvayre, A.; Salvayre, R.; Auge, N.; Pamplona, R.; Portero-Otín, M. Hyperglycemia and glycation in diabetic complications. Antioxid. Redox Signal. 2009, 11, 3071-3109.
10. Kimura, Y.; Hyogo, H.; Yamagishi, S.; Takeuchi, M.; Ishitobi, T.; Nabeshima, Y.; Arihiro, K.; Chayama, K. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J. Gastroenterol. 2010, 45, 750-757.
11. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813-820.
12. Thornalley, P.J.; Battah, S.; Ahmed, N.; Agalou, S.; Babaei-jadidi, R.; Dawnay, A. Quantitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 2003, 375, 581-592.
13. Assis, M.A. Effect of heated hyperlipid diet and regular hyperlipid diet in the formation of glycation products and reactive oxygen species in wistar rats. Master's Thesis, Federal University of Rio Grande do Sul, Porto Alegre (RS), 2009.
14. Vlassara, H.; Palace, M.R. Diabetes and advanced glycation endproducts. J. Int. Med. 2002, 251, 87-101.
15. Gaens, K.H.J.; Niessen, P.M.G.; Rensen, S.S.; Buurman, W.A.; Greve, J.W.M.; Driessen, A.; Wolfs, M.G.M.; Hofker, M.H.; Bloemen, J.G.; Dejong, C.H.; et al. Endogenous formation of Ne-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J. Hepatol. 2012, 56, 647-655.
16. Vlassara, H.; Gary, E.S. The role of advanced glycation end-products in the etiology of IR and diabetes. US Endocrinol. 2010, 6, 14-19.
17. Busch, M.; Franke, S.; Ruster, C.; Wolf, G. Advanced glycation end-products and the kidney. Eur. J. Clin. Invest. 2010, 40, 742-755.
18. Yamagishi, S.; Matsui, T.; Nakamura, K.; Inoue, H.; Takeuchi, M.; Ueda, S.; Okuda, S.; Imaizumi, T. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2008, 40, 10-15.
19. Patel, R.; Baker, S.S.; Liu, W.; Desai, S.; Alkhouri, R.K.R.; Mastrandrea, L.; Sarfraz, A.; Cai, W.; Vlassara, H.; Patel, M.S.; et al. Effect of dietary advanced glycation end products on mouse liver. PLoS ONE 2012, 7, e35143.
20. Edeas, M.; Attaf, D.; Mailfert, A.S.; Nasu, M.; Joubet, R. Maillard reaction, mitochondria and oxidative stress: Potential role of antioxidants. Pathol. Biol. (Paris) 2010, 58, 220-225.
21. Vasconcelos, S.M.L.; Goulart, M.O.F.; Moura, J.B.F.; Benfato, V.M.M.S.B.; Kubota, L.T. Reactive oxygen and nitrogen species, antioxidants and markers of oxidative damage in human blood: The main analytical methods for their determination [in Portuguese]. Quim. Nova. 2007, 30, 1323-1338.
22. Bandeira, S.M.; Fonseca, L.J.S.; Guedes, G.S.; Rabelo, L.A.; Goulart, M.O.F.; Vasconcelos, S.M.L. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int. J. Mol. Sci. 2013, 14, 3265-3284.
23. Malaguarnera, M.; Rosa, M.D.; Nicoletti, F.; Malaguarnera, L. Molecular mechanisms involved in NAFLD progression. J. Mol. Med. 2009, 87, 679-695.
24. Styskal, J.L.; Remmen, H.V.; Richardson, A.; Salmon, A.B. Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic. Biol. Med. 2012, 52, 46-58.
25. Marra, F.; Gastaldelli, A.; Svegliati Baroni, G.; Tell, G.; Tiribelli, C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends. Mol. Med. 2008, 14, 72-81.
26. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology 2007, 45, 1366-1374.
27. Zhou, J.; Febbraio, M.; Wada, T.; Zhai, Y.; Kuruba, R.; He, Jinhan.; Lee, J.H.; Khadem, S.; Ren, S.; Li, S.; et al. Hepatic fatty acid transporter cd36 is a common target of lxr, pxr, and pparf{hook}× in promoting steatosis. Gastroenterology 2008, 134, 556-567.
28. Padoin, A.V.; Staub, H.L.; Chatkin, J.M.; Moretto, M.; Maggioni, L.; Rizzolli, J.; Mottin, C.C. Nonalcoholic fatty liver disease and the risk of cirrhosis [in Portuguese]. Sci. Med. 2008, 18, 172-176.
29. Caldwell, S.H.; Hylton, A.I. The clinical outcome of NAFLD including cryptogenic cirrhosis. In Fatty Liver Disease: NASH and Related Disorders, Farrell G.C., George J., Hall P.M., McCullough A.J., Eds.; Blackwell Publishing Ltd.: Oxford, UK, 2005; pp. 168-180.
30. Pacifico, L.; Nobili, V.; Anania, C.; Verdecchia, P.; Chiesa, C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J. Gastroenterol. 2011, 17, 3082-3091.
31. Vannia, E.; Bugianesia, E.; Kotronenb, A.; de Minicisd, S.; Yki-Järvinenb, H.; Svegliati-Baronid, G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 2010, 42, 320-330.
32. Seo, H.I.; Cho, Y.K.; Lee, W.Y.; Rhee, E.J.; Sung, K.C.; Kim, B.S.; Son, B.H.; Shin, J.H.; Joo, K.J.; Hong, H.P.; et al. Which metabolic syndrome criteria best predict the presence of non-alcoholic fatty liver disease? Diabetes Res. Clin. Pract. 2012, 95, 19-24.
33. Scheen, A.J.; Luyckx, F.H. Obesity and liver disease. Best Pract. Res. Clin. Endocrinol. Metab. 2002, 16, 703-716.
34. Utzschneider, K.M.; Kahn, S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006, 1, 4753-4761.
35. Liangpunsakul, S.; Chalasani, N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: Results from the third national health and nutrition survey (NHANES III). Am. J. Med. Sci. 2005, 329, 111-116.
36. Solís Herruzo, J.A.; García Ruiz, I.; Pérez Carreras, M.; Muñoz Yagüe, M.T. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev. Esp. Enferm. Dig. 2006, 98, 844-874.
37. Leclercq, I.A.; Morais, A.S.; Schroyen, B.; Hul, N.V.; Geerts, A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J. Hepatol. 2007, 47, 142-156.
38. Day, C.P.; James, O.F. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998, 114, 842-845.
39. Wanless, I.R.; Shiota, K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: A four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 2004, 24, 99-106.
40. Hyogo, H.; Yamagishi, S.; Iwamoto, K.; Arihiro, K.; Takeuchi, M.; Sato, T.; Ochi, H.; Nonaka, M.; Nabeshima, Y.; Inoue, M.; et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2007, 22, 1112-1119.
41. Kumar, A.; Sharma, A.; Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Kohliy, K.K.; Bhansaliz, A. Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis. J. Clin. Exp. Hepatol. 2013, 3, 12-18.
42. Uribarri, J.; Cai, W.; Peppa, M.; Goodman, S.; Ferrucci, L.; Striker, G.; Vlassara, H. Circulating glycotoxins and dietary advanced glycation end products: Two links to inflammatory response, oxidative stress, and aging. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62, 427-433.
43. Piarulli, F.; Sartore, G.; Lapolla, A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: A clinical update. Acta Diabetol. 2013, 50, 101-110.
44. Yamagishi, S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) invascular damage in diabetes. Exp. Gerontol. 2011, 46, 217-224.
45. Schmidt, A.M.; Stern, D.M. RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab. 2000, 11, 368-375.
46. Gelain, D.P.; Pasquali, M.A.B.; Caregnato, F.F.; Moreira, J.C.F. Vitamin A (retinol) up-regulates the receptor for advanced glycation end products (RAGE) through p38 and Akt oxidant-dependent activation. Toxicology 2011, 289, 38-44.
47. Vasques, L.M. Regulation of receptors for advanced glycation end products (RAGE) by vitamin A. Master's Thesis, Federal University do Rio Grande do Sul, Porto Alegre (RS), Brazil, 2011.
48. Kuhla, A.; Trieglaff, C.; Vollmar, B. Role of age and uncoupling protein-2 in oxidative stress, RAGE/AGE interaction and inflammatory liver injury. Exp. Gerontol. 2011, 46, 868-876.
49. Yilmaz, Y.; Ulukaya, E.; Gul, O.O.; Arabul, M.; Gul, C.M.; Atug, O.; Oral, A.Y.; Aker, S.; Dolar, E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin. Biochem. 2009, 42, 802-807.
50. Hudson, B.I.; Harja, E.; Moser, B.; Schmidt, A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: The next C-reactive protein? Arterioscler. Thromb. Vasc. Biol. 2005, 25, 879-882.
51. Geroldi, D.; Falcone, C.; Emanuele, E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr. Med. Chem. 2006, 13, 1971-1978.
52. Friedman, S.L. Targeting siRNA to arrest fibrosis. Nat. Biotechnol. 2008, 26, 399-400.
53. Desic, S.D.; Aragon, I.B. The FAST index-A highly sensitive indicator of the heat impact on infant formula model. Food Chem. 2011, 124, 1043-1049.
54. Cai, W.; He, J.C.; Zhu, L.; Chen, X.; Wallenstein, S.; Striker, G.E.; Vlassara, H. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am. J. Pathol. 2007, 170, 1893-1902.
55. Rolo, A.P.; Teodoro, J.S.; Palmeira, C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52, 59-69.
56. Veteläinen, R.; van Vliet, A.; van Gulik, T.M. Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J. Gastroenterol. Hepatol. 2007, 22, 1526-1533.
57. Reis, J.S.; Veloso, C.A.; Mattos, R.T.; Purish, S.; Nogueira-Machado, J.A. Oxidative stress: Review of metabolic signaling in type 1 diabetes (in Portuguese). Arq. Bras. Endocrinol. Metab. 2008, 52, 1096-1105.
58. Nomura, K.; Yamanouchi, T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2012, 23, 203-208.
59. Guimarães, E.L.M.; Empsen, C.; Geerts, A.; Grunsven, L.A.V. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J. Hepatol. 2010, 52, 389-597.
60. Trauner, M.; Arrese, M.; Wagner, M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta 2010, 1801, 299-310.
61. Koek, G.H.; Liedorp, P.R.; Bast, A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin. Chim. Acta 2011, 412, 1297-1305.
62. Brenner, C.; Galluzzi, L.; Kepp, O.; Kroemer, G. Decoding cell death signals in liver inflammation. J. Hepatol. 2013, 59, 583-594.